![](https://www.nanalyze.com/app/uploads/2024/02/10X-Genomics-Teaser-1024x683.jpg)
When not busy trying to resurrect the wooly mammoth, geneticist George Church spends his time launching new biotech companies at a pace nearly on par with SpaceX sending rockets into space. At last count, he had co-founded or otherwise helped kickstart about 50 different companies – many of which have gained some amount of traction. For instance, Ginkgo Bioworks (DNA) acquired one of his very first ventures, a synthetic biology startup called Gen9 that we covered at the time. In fact, we’ve written about a number of the Harvard professor’s many businesses, and even held shares in another early venture, Editas Medicine (EDIT), before exiting our position in 2022.
![Highlights of 10X Genomics](https://www.nanalyze.com/app/uploads/2024/02/10X-Genomics-growth-overview.jpg)
Another one of Church’s earliest startups was a company called ReadCoor whose intellectual property (IP) would eventually become a key technology that is currently helping fuel growth for 10X Genomics (TXG). The biotech company recently released its 2023 year-end results. Revenue climbed 20% year-over-year to more than $618 million after growth hit a wall the prior year in 2022. New product platforms are helping revive growth, though the company’s flagship platform is still flagging and gross margins are still shrinking. Let